Case study C: GSK‚ a merger too far? 1- Derive three opportunities and three threats for GSK by first making the PESTEL analysis of the macro-environment surrounding the pharmaceutical industry. (9 points) * PESTEL analysis of the pharmaceutical industry: Political: Since the creation of healthcare insurance‚ companies have to conform themselves to two kinds of systems: 1) The universal system applied for example in France‚ with less demand in new technologies. 2) The very selective anglo-saxon
Premium Pharmacology Generic drug Pharmaceutical industry
Core issue: The case describes the events which lead to the merger of two large pharmaceutical giant Glaxo welcome and SmithKline beecham which lead to the formation of the entity GlaxoSmithKline. The core concern of the case is that although the newly merged company has invested heavily in R&D there is little evidence of success. Identification of supporting issues: These are some of the other issues that came up in the case which lead to the overall lack of success: * Significant
Premium
EVALUATION OF THE FINANCIAL PERFORMANCE OF GLAXOSMITHKLINE 2008 AND 2009 BACKGROUND OF THE COMPANY GSK is the world’s largest pharmaceutical company. It has a 7% share of the global pharmaceutical market‚ 26% of all vaccine sales‚ and 17% of all anti-invectives. It was formed with the merger of two top pharmaceutical companies‚ Glaxo Wellcome Plc and SmithKline Beecham Plc in December 2000. “GSK’s history dates back to 1715‚ when Plough Court pharmacy‚ a predecessor to SmithKline Beecham‚ was
Premium Generally Accepted Accounting Principles
healthcare goods. ‚ however there is much dispute over the motives behind the merger and what Glaxo Wellcome sought to gain through the collaboration. This is of particular concern as following the merger‚ many shareholders and city analysts have criticised the firm for not yielding the predicted benefits from the merger‚ particularly with regard to an innovative product pipeline. It has been argued that the purpose of the merger was to serve as a method of consolidating Glaxo Wellcome ’s position in the
Premium Pharmaceutical industry
My topic was Post Merger Integration. Post merger integration is one of the methods used after merger and acquisition. It can help companies to increase their value after M&A has completed. When companies merge‚ high cost of synergies‚ related job cuts‚ fast decisions and clear statements are required. When PMI is carried out‚ a more relaxed transition can be made. Post-merger integration brings intangible and non-cash values after M&A has taken place. After M&A has occurred‚ companies
Premium Mergers and acquisitions
4.1 INTRODUCTION GSK Bangladesh Limited has been an active part of the pharmaceutical scenario of Bangladesh for a long time now. In Bangladesh‚ its functions are surrounded by 3 basic categories of pharmaceutical products. These are: a) Locally manufactured pharmaceutical products like Ventolin‚ Berin‚ Kefdrin‚ Amoxil‚ Dermovate‚ Zantac‚ Lamictal etc. b) Imported pharmaceutical products like Alkeran‚ Leukeran‚ Seretide etc. c) Vaccines like Engerix-B‚ Havrix‚ Hiberix‚ Varilrix etc
Premium Generally Accepted Accounting Principles Balance sheet Financial ratios
COMPANY OVERVIEW GlaxoSmithKline (GSK) is one of the world’s leading research-based pharmaceutical and healthcare companies. The company is engaged in the discovery‚ development‚ manufacturing and marketing of pharmaceutical and consumer health-related products. The company primarily operates in 120 countries and its products are sold in more than 150 countries. GSK is headquartered in Brentford‚ the UK and employed 99‚913 people as of December 31‚ 2009. The company recorded revenues of £28‚368
Premium
Whitepaper on Post Merger People Integration CONTENTS Merger and Acquisition: The story so far Post Merger People Integration Addressing Key People and Organization Risks 1 5 7 Managing Change during Post Merger Integration 13 Addressing Key Leadership Challenges 17 © 2011 KPMG‚ an Indian Partnership and a member firm of the KPMG network of independent member firms affiliated with KPMG International Cooperative (“KPMG International”)‚ a Swiss entity. All rights reserved. FOREWORD As the
Premium Mergers and acquisitions Management Due diligence
Specialisation Accounting and Finance Post-Merger Performance of North American‚ European and UK acquirers A study of synergy advantages: M&As during 1981-1999 in the Utilities‚ Manufacturing and Services industries Author: EUR study number: Thesis supervisor: Finish date: M.B. Gmelich 307381 Dr. W. de Maeseneire September 2011 ABSTRACT This thesis empirically investigates the antecedents of abnormal return and operating performance improvement through mergers and acquisitions in Europe‚ the
Premium Mergers and acquisitions Free cash flow Cash flow
history. This project looked at GlaxoSmithKline in Dungarvan‚ Co. Waterford. GSK has been manufacturing in Dungarvan since 1981 and has two manufacturing sites there. The first is the Oral care facility which was set up in 1981 and the second is the over the counter medicine site which was set up in 1987. Many of the company’s flagship brands are produced in Dungarvan including Panadol‚ Polygrip and NiQuitn. According to the GSK Website “Products produced in Dungarvan are exported to more than 70 countries
Premium